Coverage For Off-Label Cancer Drugs, Genomic Tests Tackled In Policy Report
This article was originally published in The Pink Sheet Daily
The Green Park Collaborative seeks public comments on recommended guidelines for insurance coverage of tumor profiling through next-generation DNA sequencing and off-label treatment of targeted cancer drugs.
You may also be interested in...
Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.
Medicare national coverage determination for Alzheimer’s drugs has been a ‘game changer’ in terms of motivating industry to boost diversity in clinical studies in the disease, trial expert says.
With a slim House majority, will Republicans wade into Medicare coverage policy for a promising Alzheimer’s drug and the new Medicare price negotiation program? Democratic Senate could offer ‘counter oversight’ hearings.